Biotech Values

[DewDiligence]

WSJ profiles Claude Wischik, founder of TauRx:

http://online.wsj.com/article/SB10000872396390443624204578060941988428604.html

In the early 1990s, Dr. Wischik and his colleagues compared the postmortem brains of Alzheimer's sufferers against those of people who had died without dementia, to see how their levels of amyloid and tau differed. They found that both healthy brains and Alzheimer's brains could be filled with amyloid plaque, but only Alzheimer's brains contained aggregated tau. What's more, as the levels of aggregated tau in a brain increased, so did the severity of dementia.

The article mentions the (suspect) publication of only partial data from the phase-2 study.